Survey for Individuals Living with Neovascular Age-related Macular Degeneration

We hope this message finds you well. Prevent Blindness is helping VOZ Advisors, a consulting firm that specializes in patient advocacy and engagement during the drug development process. They are currently working with a global biopharmaceutical company to gain a deeper understanding of the challenges and experiences faced by individuals living with neovascular age-related macular degeneration [Read More]

IZERVAY™, is the Second Treatment Approved by the FDA for Geographic Atrophy 

IZERVAY™ reduced the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials. IZERVAY slowed loss of photoreceptors and disease progression as early as six months. Astellas Pharma Inc.  announced on August 5, 2023 that the U.S. Food and Drug Administration (FDA) approved IZERVAY™ (avacincaptad pegol intravitreal solution) for the [Read More]

Prevent Blindness Accepting Applications For New ASPECT Program

The application period is now open for all who wish to participate in the ASPECT (Advocacy, Support, Perspective, Empowerment, Communication, and Training) Patient Engagement Program at Prevent Blindness. Individuals with vision impairment or blindness are welcome to participate, as well as allies (i.e. parents or guardians, care partners, nonprofit representatives, multidisciplinary clinicians, eye care providers, [Read More]

Free Updated “GuideMe” Book for AMD Now Online

Similar to a practicing low vision therapist, the GuideMe Book for age-related macular degeneration gathers personal information from the client, then offers guidance and resources unique to the client’s personal needs and goals. Prevent Blindness, a patient advocacy organization preserving vision and eye health for more than 115 years, continues to give the gift of [Read More]